Friday 6 November 2026 Export XBIO’s income statement to Excel — free account

Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 million, up 19.0% from fiscal 2024.

Revenue: +12.0%
EPS: +8.89%
Free cash flow: −128.1%

Quarter to June 2026, against a year earlier

Operating cash flow growth 3 yrs

1.87 0.00 0.00%

Follow XBIO

Alert me

Market cap: $4.4M
P/E: 0.0×
Fwd P/E: −0.9×
Dividend yield: —
F-score: 5/9
Altman Z: −30.91
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 13.70%

Capital & Financial Ratios $m

Size

Market Cap 4.37

Revenue ttm 3.26

Net income ttm (2.48)

Free cash flow ttm (2.31)

Net debt Q (6.47)

Valuation

P/E 0.00

Forward P/E (0.89)

Price / sales 1.32

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.71

Financial health

Current ratio Q 7.43

Debt / equity Q 0.00

Interest coverage Q (12.49)

Growth

Revenue growth Q +11.99%

Operating income growth Q −34.14%

EPS, this year +20.62%

EPS, next year A −62.75%

Revenue, next year A −23.33%

EPS, past 5 yrs —

EPS, next 5 yrs A +49.05%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 13.76%

10-year low 10-year high

P/B against its own 10 years 35.34%

10-year low 10-year high

EV/FCF against its own 10 years 31.84%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	9	6	8	6
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	10	7	8	7

	2023	2024	2025	Q'26
Payables	0	0	0	0
ST’ Debt	—	—	—	—
Other	—	—	—	—
	1	1	1	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	46.78%	20.36%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	1.13%	(9.55%)	(18.47%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY25 Estimate −0.64 Actual −0.45

−0.93 −0.71 −0.48 −0.26 −0.04

Q2 FY24 Met 0.00

Q3 FY24 Miss −0.14

Q1 FY25 Beat +0.13

Q2 FY25 Beat +0.19

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q2 FY24	−0.83	−0.83	Met by 0.00
Q3 FY24	−0.14	−0.28	Miss by 0.14
Q1 FY25	−0.72	−0.59	Beat by 0.13
Q2 FY25	−0.64	−0.45	Beat by 0.19

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.20)	(0.41)	—	—	—
’25	(0.59)	(0.45)	(0.33)	(0.27)	(1.58)
’24	(0.78)	(0.83)	(0.28)	(0.68)	(2.57)
’23	(0.60)	(0.69)	(0.69)	(0.77)	(2.71)
’22	(1.20)	(1.90)	(0.60)	(1.00)	(4.60)
’21	(1.50)	(1.30)	(1.30)	(1.36)	(5.49)
’20	(1.90)	(1.50)	(12.00)	(1.50)	(17.00)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	1	—	—	—
’25	1	1	1	1	3
’24	1	1	1	1	3
’23	1	1	1	1	3
’22	0	0	0	0	2
’21	0	0	0	0	1
’20	0	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(1)	0	(1)	0	(2)
’24	(1)	(1)	0	(1)	(3)
’23	(1)	(1)	(1)	(1)	(4)
’22	(2)	(1)	(1)	(1)	(5)
’21	(2)	(1)	(1)	(1)	(5)
’20	(1)	(1)	(1)	(1)	(4)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(1)	0	(1)	0	(2)
’24	(1)	(1)	0	(1)	(3)
’23	(1)	(1)	(1)	(1)	(4)
’22	(2)	(1)	(1)	(1)	(5)
’21	(2)	(1)	(1)	(1)	(5)
’20	(1)	(1)	(1)	(1)	(4)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	3	8	—	0	0	1	2	3	3	3	3		(0.1%)	2	2	7	+35.3%
	Gross margin, %	100.00	97.94	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00		0.0 pt	Powerpack Xenetic Biosciences, Inc.’s next three years, line by line Analysts expect revenue to grow 35.3% a year to 2028 — faster than the −0.1% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(54)	(4)	(7)	(13)	(14)	(6)	(7)	(4)	(4)	(3)	(2)		(28.4%)
	EBT margin, %	(1,806.87)	(47.40)	0.00	(74,707.60)	(3,161.36)	(486.36)	(383.88)	(162.78)	(158.39)	(90.07)	(75.90)		+1,716.8 pt
	Net income	(54)	(4)	(7)	(13)	(11)	(6)	(7)	(4)	(4)	(3)	(2)		(28.4%)
Per share, $
Per share, $	Revenue	48.47	105.06	0.00	0.06	0.68	1.13	1.20	1.66	1.62	1.75	1.42		(30.9%)
	Earnings	(941.18)	(49.22)	(96.04)	(63.30)	(17.00)	(5.10)	(4.60)	(2.71)	(2.57)	(1.58)	(1.21)		(50.8%)
	Cash flow	(141.96)	20.70	(85.50)	(22.44)	(6.68)	(4.61)	(3.27)	(2.69)	(1.83)	(1.34)	(1.01)		(40.4%)
	Capex	(0.27)	(0.13)	0.30	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00		n/m
	Free cash flow	(142.23)	20.57	(85.20)	(22.43)	(6.68)	(4.61)	(3.27)	(2.69)	(1.83)	(1.34)	(1.01)		(40.4%)
	Book value	261.22	198.08	131.12	60.36	19.11	17.90	9.59	6.41	3.90	4.35	2.65		(36.6%)
	Shares, m	0	0	0	0	1	1	1	2	2	2	2		+44.5%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	0.00	0.00	—	0.48	29.85	11.42	2.54	2.15	2.46	1.24	1.32		5.6
	P/B	2.48	1.15	—	0.24	1.07	0.72	0.32	0.56	1.02	0.50	0.71		0.9
	EV/Sales	0.00	0.00	—	(0.60)	6.06	(3.32)	(4.47)	(0.94)	0.45	(1.03)	(0.32)		(0.4)
	EV/FCF	(4.22)	8.08	—	0.80	(0.62)	0.81	1.64	0.58	(0.40)	1.34	0.45		0.9
Cash, $m
Cash, $m	Operating cash flow	(9)	1	(6)	(6)	(4)	(5)	(5)	(4)	(3)	(2)	(2)		(13.9%)
	Capex	0	0	0	0	—	—	—	—	—	—	0		n/m
	Free cash flow	(9)	1	(6)	(6)	(4)	(5)	(5)	(4)	(3)	(2)	(2)		(13.9%)
Balance, $m
Balance, $m	Working capital	6	4	0	10	11	17	13	9	6	7	6		+1.0%
	Net debt	(4)	(6)	(1)	(10)	(12)	(18)	(13)	(9)	(6)	(8)	(6)		+7.5%
	Shareholders’ equity	16	14	10	17	12	18	14	10	6	7	6		(8.3%)
Returns, %
Returns, %	ROA	(307.49)	(17.91)	(43.46)	(100.39)	(62.74)	(34.22)	(37.95)	(32.65)	(45.24)	(35.12)	(40.17)		+272.4 pt
	ROIC	(245.91)	(25.63)	(49.03)	(117.66)	(1,266.33)	(2,389.72)	(763.68)	(347.32)	0.00	0.00	0.00		+245.9 pt
	ROE	(511.45)	(23.60)	(60.31)	(133.18)	(74.05)	(36.89)	(40.91)	(35.28)	(50.13)	(40.01)	(47.05)		+471.4 pt
People
People	Employees	7	5	4	4	4	4	4	4	2	2	—		(13.0%)
	Revenue/emp, $m	0.43	1.52	0.00	0.00	0.11	0.29	0.43	0.64	1.25	1.49	—		+14.8%

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 25 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NIKI Niki BioSolutions, Inc.	$4.7M	— (loss-making)	31.9×	−32.36% (below 0%: shrinking)	+69.51% (above 0%: growing)	+58.14% (above 0%: growing)	(154.22%)	0.00%	Compare
SKYE Skye Bioscience, Inc.	$4.6M	— (loss-making)	—	−34.71% (below 0%: shrinking)	n/m	+34.84% (above 0%: growing)	72.71%	0.00%	Compare
ADTX Aditxt, Inc.	$4.4M	— (loss-making)	—	+1,120.00% (above 0%: growing)	n/m	+60.82% (above 0%: growing)	23.77%	(35,753.28%)	Compare
AZTR Azitra, Inc.	$4.4M	1.3×	— (loss-making)	−93.38% (below 0%: shrinking)	n/m	−19.55% (below 0%: shrinking)	100.00%	0.00%	Compare
XBIO Xenetic Biosciences, Inc.	$4.4M	— (loss-making)	— (loss-making)	+11.99% (above 0%: growing)	n/m	−128.11% (below 0%: shrinking)	100.00%	(147.09%)
OSRH OSR Health, Inc.	$4.1M	— (loss-making)	—	−72.20% (below 0%: shrinking)	n/m	−398.76% (below 0%: shrinking)	27.43%	(960.69%)	Compare
NCNA NuCana PLC Sponsored ADR	$4.0M	— (loss-making)	—	—	n/m	+55.66% (above 0%: growing)	0.00%	0.00%	Compare
PMCB Nuvilex Inc.	$4.0M	— (loss-making)	—	−103.94% (below 0%: shrinking)	n/m	+60.84% (above 0%: growing)	100.00%	0.00%	Compare
CELZ Creative Medical Technology Holdings, Inc.	$4.0M	— (loss-making)	— (loss-making)	0.00%	n/m	−27.05% (below 0%: shrinking)	66.67%	0.00%	Compare
Median of peers	$4.2M	—	—	−34.71%	—	+45.25%	47.05%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 31 October 2025

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2024	481.17k	469.66k	30.93

Ownership

Directors and executive officers, together 7.60%

Dr. Dmitry Genkin 9.50%

CLS Therapeutics, Ltd. 6.50%

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Xenetic Biosciences, Inc. (XBIO) Latest News

15 Oct

Impact 4 · 8:46 AM · ACCESS Newswire

Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma

16 Sep

Impact 5 · 10:30 AM · InvestorsHub

Xenetic Biosciences Announces All-Stock Merger with Santersus, Leaving Existing Shareholders with 15% Stake

Impact 4 · 10:28 AM

Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition

Impact 4 · 7:00 AM

Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics

7 Aug

Impact 3 · 8:35 AM

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

1 Jun

Impact 4 · 9:02 AM · ACCESS Newswire

Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival

13 May

Impact 3 · 8:05 AM · ACCESS Newswire

Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform

22 Apr

Impact 3 · 9:00 AM · ACCESS Newswire

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

13 Mar

Impact 4 · 8:30 AM · ACCESS Newswire

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses

Impact 3 · 8:00 AM · ACCESS Newswire

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

12 Mar

Impact 3 · 6:32 PM · Associated Press Finance

Xenetic Biosciences: Q4 Earnings Snapshot

19 Nov

Impact 4 · 8:45 AM

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

13 Nov

Impact 3 · 8:45 AM · ACCESS Newswire

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

12 Nov

Impact 3 · 5:43 PM · Associated Press Finance

Xenetic Biosciences: Q3 Earnings Snapshot

10 Oct

Impact 3 · 9:30 AM · ACCESS NewswireMT NewswiresMT NewswiresMT NewswiresMT NewswiresMT NewswiresMT Newswires

Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock

13 Aug

Impact 3 · 8:00 AM

Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

12 Aug

Impact 3 · 6:25 PM

Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

Impact 3 · 5:26 PM · Associated Press Finance

Xenetic Biosciences: Q2 Earnings Snapshot

30 Jul

Impact 4 · 9:00 AM · ACCESS Newswire

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

23 Jul

Impact 4 · 8:30 AM

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

8 Jul

Impact 4 · 9:00 AM

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

14 May

Impact 4 · 8:05 AM · ACCESS Newswire

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

9 Apr

Impact 3 · 9:15 AM

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

26 Mar

Impact 4 · 9:00 AM · ACCESS Newswire

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma

20 Mar

Impact 3 · 7:00 AM

Xenetic Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

19 Mar

Impact 4 · 8:05 AM · ACCESS Newswire

Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results

27 Feb

Impact 4 · 9:15 AM · ACCESS Newswire

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

17 Dec

Impact 4 · 9:15 AM · ACCESSWIRE

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

16 Dec

Impact 4 · 9:00 AM · ACCESSWIRE

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

5 Dec

Impact 4 · 8:45 AM · ACCESSWIRE

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Xenetic Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 31 October 2025

Chief executive’s pay

Ownership

Xenetic Biosciences, Inc. (XBIO) Latest News

15 Oct

16 Sep

7 Aug

1 Jun

13 May

22 Apr

13 Mar

12 Mar

19 Nov

13 Nov

12 Nov

10 Oct

13 Aug

12 Aug

30 Jul

23 Jul

8 Jul

14 May

9 Apr

26 Mar

20 Mar

19 Mar

27 Feb

17 Dec

16 Dec

5 Dec

Stockrow Weekly